Listen
VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B
INFECTIOUS DISEASES - New medicinal product
Opinions on drugs -
Posted on
Jan 18 2018
Reason for request
Inclusion
- VAXELIS is a hexavalent vaccine which has Marketing Authorisation for the primary and booster vaccination against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections and hepatitis B, in infants from 6 weeks of age.
- There are two other hexavalent vaccines authorised in France for the primary and booster vaccination in infants: INFANRIX HEXA and HEXYON. The immunogenicity of VAXELIS is not inferior to that of INFANRIX HEXA and its safety profile is comparable despite a higher frequency of local reactions and fever.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
